Hillstream Biopharma Inc. has announced initial results evaluating the synergy of ferroptosis inducer HSB-1216 (quatramer salinomycin) with anti-PD-1 antibody pembrolizumab in the Calu-1 KRAS G12C-mutated non-small-cell lung cancer (NSCLC) cell line.